Worldwide Study Finder

Not applicableCompletedINTERVENTIONAL

Intramuscular Injection of Human Chorionic Gonadotropin in Frozen Embryo Transfer Cycles

ClinicalTrials.gov · NCT04855383 · Registry updated: 2024-01-05

Condition / research focus: Embryo Implantation
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2020-07-01. Completion: 2023-06-20 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles (drug) — also listed as: The effect of intramuscular injection of triple doses of human chorionic gonadotropin on embryo implantation

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Tehran, Iran

Phase 1 / Phase 2CompletedINTERVENTIONAL

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

ClinicalTrials.gov · NCT02525029 · Registry updated: 2023-12-14

Condition / research focus: Graft vs Host Disease
Sponsor: Masonic Cancer Center, University of Minnesota
Countries with listed sites: United States
Registry dates and results: Start: 2016-03. Completion: 2022-04 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pregnyl® (drug) — also listed as: Human chorionic gonadotropin (hCG)

Where the study takes place — 1 listed sites

Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve

ClinicalTrials.gov · NCT05567731 · Registry updated: 2023-12-07

Condition / research focus: Intracytoplasmic Sperm Injection; GnRH Agonist; Infertility; Ovarian Reserve
Sponsor: Tanta University
Countries with listed sites: Egypt
Registry dates and results: Start: 2022-10-15. Completion: 2023-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ultrashort GnRHa (drug) — also listed as: ultrashort gonadotropin-releasing hormone (GnRH) agonist
short GnRHa (drug) — also listed as: short gonadotropin-releasing hormone (GnRH) agonist
long GnRHa (drug) — also listed as: long gonadotropin-releasing hormone (GnRH) agonist

Where the study takes place — 1 listed sites

Ahmed M.E. Ossman
Tanta, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger

ClinicalTrials.gov · NCT06142708 · Registry updated: 2023-11-21

Condition / research focus: Ovarian Stimulation; Human Chorionic Gonadotropin; Oocyte Donors
Sponsor: Embryolab Fertility Clinic
Countries with listed sites: Greece
Registry dates and results: Start: 2023-11-01. Completion: 2026-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dual trigger (human chorionic gonadotropin plus GnRH-agonist) (drug)
GnRH-agonist only trigger (drug)

Where the study takes place — 1 listed sites

Embryolab Fertility Clinic
Thessaloniki, Greece
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS

ClinicalTrials.gov · NCT02436226 · Registry updated: 2023-10-31

Condition / research focus: Infertility; Polycystic Ovarian Syndrome
Sponsor: Mohamed Sayed Abdelhafez
Countries with listed sites: Egypt
Registry dates and results: Start: 2016-03. Completion: 2023-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Clomiphene citrate and Human chorionic gonadotropin (HCG) (drug) — also listed as: Clomid and Choriomon
Clomiphene citrate (drug) — also listed as: Clomid

Where the study takes place — 1 listed sites

Obstetrics and Gynecology Department in Mansoura University Hospital
Al Mansurah, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients

ClinicalTrials.gov · NCT02330757 · Registry updated: 2023-10-30

Condition / research focus: Infertility
Sponsor: Mansoura University
Countries with listed sites: Egypt
Registry dates and results: Start: 2016-10-10. Completion: 2024-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Estradiol valerate (drug) — also listed as: Cycloprogynova (white tablets)
Sequential Clomiphene citrate and Gonadotropin (drug) — also listed as: Sequential Clomid and Menogon

Where the study takes place — 2 listed sites

Fertility Care Unit (FCU) in Mansoura University Hospital
Al Mansurah, Dakahlia Governorate, Egypt
Site recruitment: Recruiting
Private fertility care centers
Al Mansurah, Dakahlia Governorate, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration

ClinicalTrials.gov · NCT02330770 · Registry updated: 2023-10-30

Condition / research focus: Infertility
Sponsor: Mansoura University
Countries with listed sites: Egypt
Registry dates and results: Start: 2016-06-06. Completion: 2024-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRHa and HCG (drug) — also listed as: Decapeptyl and Pregnyl
GnRHa then HCG (single low-dose) (drug) — also listed as: Decapeptyl then Pregnyl
GnRHa then HCG (multiple low-doses) (drug) — also listed as: Decapeptyl then Pregnyl

Where the study takes place — 2 listed sites

Fertility Care Unit (FCU) in Mansoura University Hospital
Al Mansurah, Dakahlia Governorate, Egypt
Site recruitment: Recruiting
Private fertility care centers
Al Mansurah, Dakahlia Governorate, Egypt
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

ClinicalTrials.gov · NCT04724486 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2020-08-22. Completion: 2022-07-15 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

ClinicalTrials.gov · NCT04727684 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Infertility; Intracytoplasmic Sperm Injection; Polycystic Ovary Syndrome
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2020-08-22. Completion: 2022-05-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

ClinicalTrials.gov · NCT04724343 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2019-12-22. Completion: 2022-07-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

ClinicalTrials.gov · NCT04727671 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility; Polycystic Ovary Syndrome
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2019-12-22. Completion: 2021-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Hormonal Stimulation of Spermatogenesis

ClinicalTrials.gov · NCT05483621 · Registry updated: 2023-10-19

Condition / research focus: Azoospermia, Nonobstructive
Sponsor: Egymedicalpedia
Countries with listed sites: Egypt
Registry dates and results: Start: 2021-03-01. Completion: 2022-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Beta-hCG (drug)

Where the study takes place — 1 listed sites

Urology department - faculty of medicine, South Valley university
Qina, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

ClinicalTrials.gov · NCT04447872 · Registry updated: 2023-10-16

Condition / research focus: Infertility; Diminished Ovarian Reserve; IVF
Sponsor: Northwell Health
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-15. Completion: 2025-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Timing of injectable gonadotropins (procedure)

Where the study takes place — 1 listed sites

Northwell Fertility
Manhasset, New York, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

Assessing Ketorolac (Toradol) at Oocyte Retrieval

ClinicalTrials.gov · NCT06026553 · Registry updated: 2023-09-07

Condition / research focus: Infertility; Infertility, Female; Oocyte Retrieval; Postoperative Pain; Embryo Transfer
Sponsor: Shady Grove Fertility Reproductive Science Center
Countries with listed sites: United States
Registry dates and results: Start: 2022-08-10. Completion: 2025-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ketorolac (Toradol) (drug)
Placebo (saline) (other)

Where the study takes place — 2 listed sites

Shady Grove Fertility Reproductive Science Center
Rockville, Maryland, United States
Site recruitment: Recruiting
Shady Grove Fertility Reproductive Science Center
Fairfax, Virginia, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

ClinicalTrials.gov · NCT03495609 · Registry updated: 2023-09-07

Condition / research focus: hCG; BRCA1 Mutation; BRCA2 Mutation
Sponsor: University Hospital, Ghent
Countries with listed sites: Belgium
Registry dates and results: Start: 2016-02-17. Completion: 2018-12-18 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovitrelle (drug)

Where the study takes place — 1 listed sites

Ghent University Hospital
Ghent, East-Flanders, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

ClinicalTrials.gov · NCT03564509 · Registry updated: 2023-08-31

Condition / research focus: Controlled Ovarian Stimulation
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Belgium · Czechia · Denmark · Spain · United Kingdom
Registry dates and results: Start: 2018-05-14. Completion: 2020-01-08 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

FE 999302 (1 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (2 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (4 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (8 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (12 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
Placebo and follitropin delta (other)

Where the study takes place — 20 listed sites

Universitair Ziekenhuis Gent (UZ Gent)
Ghent, Belgium
Site recruitment: Not reported
Universitair Ziekenhuis Brussel
Jette, Belgium
Site recruitment: Not reported
Institut fur Reproduktionsmedizin und Genetik
Karlovy Vary, Czechia
Site recruitment: Not reported
Fertimed
Olomouc, Czechia
Site recruitment: Not reported
GYNEM
Prague, Czechia
Site recruitment: Not reported
IVF CUBE
Prague, Czechia
Site recruitment: Not reported
Aalborg University Hospital
Aalborg, Denmark
Site recruitment: Not reported
Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Dansk Fertilitetsklinik
Frederiksberg, Denmark
Site recruitment: Not reported
Hvidovre Hospital
Hvidovre, Denmark
Site recruitment: Not reported
Dexeus Woman's Health
Barcelona, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Bilbao
Leioa, Spain
Site recruitment: Not reported
GINEFIV - Clinica Belen Location
Madrid, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Madrid
Madrid, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Sevilla
Seville, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Valencia
Valencia, Spain
Site recruitment: Not reported
Glasgow Royal Infirmary
Glasgow, United Kingdom
Site recruitment: Not reported
Liverpool Women's Hospital
Liverpool, United Kingdom
Site recruitment: Not reported
Guy's and St Thomas' NHS Trust
London, United Kingdom
Site recruitment: Not reported
Kings College (Assisted Conception Unit)
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome

ClinicalTrials.gov · NCT05969834 · Registry updated: 2023-08-01

Condition / research focus: Infertility
Sponsor: Mansoura University
Countries with listed sites: Egypt
Registry dates and results: Start: 2021-03-31. Completion: 2022-08-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

uHCG (drug) — also listed as: Choriomon
rHCG (drug) — also listed as: Ovitrelle
uHCG and GnRHa (drug) — also listed as: Decapeptyl and Choriomon

Where the study takes place — 1 listed sites

Royal Center
Al Mansurah, Dakahlia Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Dual Trigger for Elective Fertility Preservation

ClinicalTrials.gov · NCT04992468 · Registry updated: 2023-07-25

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2021-10-05. Completion: 2023-04-25 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovulation triggering with GnRH-a+rhCG (drug)
Ovulation triggering with GnRH-a (drug)

Where the study takes place — 1 listed sites

Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men

ClinicalTrials.gov · NCT04189133 · Registry updated: 2023-07-20

Condition / research focus: Acquired Hypogonadotropic Hypogonadism
Sponsor: Azienda Ospedaliero-Universitaria di Modena
Countries with listed sites: Italy
Registry dates and results: Start: 2022-01-19. Completion: 2026-01-18 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lutropin alfa (drug) — also listed as: LH
Human chorionic gonadotropin (drug) — also listed as: hCG

Where the study takes place — 5 listed sites

Fondazione IRCCS Ca ' Grande Ospedale Maggiore Policlinico
Milan, Italy
Site recruitment: Not yet recruiting
Unit of Endocrinology of Modena
Modena, Italy
Site recruitment: Recruiting
Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università degli Studi di Napoli "Federico II"
Naples, Italy
Site recruitment: Not yet recruiting
Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza - University of Rome
Rome, Italy
Site recruitment: Not yet recruiting
ivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin
Turin, Italy
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome

ClinicalTrials.gov · NCT05638529 · Registry updated: 2023-07-03

Condition / research focus: Ovarian Hyperstimulation Syndrome; Infertility, Female
Sponsor: Mount Sinai Hospital, Canada
Countries with listed sites: Canada
Registry dates and results: Start: 2019-05-01. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pregnyl (1,500) IU (drug) — also listed as: Hcg
1.5 mL of normal saline (drug) — also listed as: Normal Saline

Where the study takes place — 1 listed sites

Mount Sinai Hospital, Fertility Clinic
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Find a study

Registry search results

Intramuscular Injection of Human Chorionic Gonadotropin in Frozen Embryo Transfer Cycles

Explore the world’s study registries

Worldwide

Africa

Americas

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve

The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger

Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS

HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients

Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

Hormonal Stimulation of Spermatogenesis

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

Assessing Ketorolac (Toradol) at Oocyte Retrieval

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome

Dual Trigger for Elective Fertility Preservation

Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men

Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome

Asia

Middle East

Europe

Oceania